Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Pacira BioSciences, Inc. (PCRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/03/2023 8-K Quarterly results
Docs: "Pacira BioSciences Reports First Quarter 2023 Financial Results"
02/28/2023 8-K Quarterly results
Docs: "Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results — Record revenues of $667 million in 2022"
08/03/2022 8-K Quarterly results
Docs: "Pacira BioSciences Reports Second Quarter 2022 Financial Results"
05/04/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
11/03/2021 8-K Quarterly results
Docs: "Pacira BioSciences Reports Third Quarter 2021 Financial Results"
08/03/2021 8-K Quarterly results
Docs: "Pacira BioSciences Reports Record Revenue of $135.6 Million for the Second Quarter of 2021"
05/04/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
10/29/2020 8-K Quarterly results
Docs: "Pacira BioSciences Reports Third Quarter 2020 Financial Results and Business Update"
08/06/2020 8-K/A Quarterly results
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
02/20/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "Pacira BioSciences Reports Third Quarter 2019 Financial Results and Business Update -- Total revenues increased 25 percent over prior year to $104.7 million in third quarter -- -- Conference call today at 8:30 a.m. ET --"
08/08/2019 8-K Quarterly results
Docs: "Pacira BioSciences Reports Second Quarter 2019 Financial Results and Business Update -- Total revenues increased 22% over prior year to $102.6 million in second quarter -- -- Conference call today at 8:30 a.m. ET --"
05/02/2019 8-K Quarterly results
Docs: "Pacira BioSciences Reports First Quarter 2019 Revenues of $91.3 Million -- EXPAREL ® net product sales of $90.6 million up 22.4 percent over prior year first quarter -- -- MyoScience acquisition advances leadership in non-opioid pain management; corporate name change to Pacira BioSciences reflects expanding product portfolio -- -- Conference call today at 8:30 a.m. ET --"
02/28/2019 8-K Quarterly results
11/01/2018 8-K Quarterly results
Docs: "Pacira Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results -- EXPAREL® net product sales of $82.2 million up 23% over prior year third quarter -- -- Full-year EXPAREL net product sales guidance increased to $325 to $330 million -- -- Conference Call Today at 8:30 a.m. ET --"
08/02/2018 8-K Quarterly results
Docs: "Pacira Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results -- EXPAREL® net product sales of $80.4 million up 15% over prior year second quarter -- -- Full-year EXPAREL net product sales guidance increased to $320 to $325 million -- -- Conference Call Today at 8:30 a.m. ET --"
05/03/2018 8-K Quarterly results
Docs: "Pacira Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results -- EXPAREL® net product sales of $74.0 million up 9% over prior year first quarter -- -- Conference Call Today at 8:30 a.m. ET --"
02/28/2018 8-K Quarterly results
Docs: "Pacira Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update -- EXPAREL ® net product sales expected to be in the range of $300 to $310 million in 2018 -- -- Conference call today at 8:30 a.m. ET --"
11/08/2017 8-K Quarterly results
Docs: "Pacira Pharmaceuticals, Inc. Reports Third Quarter 2017 Financial Results -- EXPAREL® net product sales of $66.8 million up 3% over prior year third quarter -- -- Full-year EXPAREL net product sales guidance revised to $280 to $285 million -- -- Conference Call Today at 8:30 a.m. ET --"
05/04/2017 8-K Form 8-K - Current report
11/02/2016 8-K Form 8-K - Current report
08/04/2016 8-K Form 8-K - Current report
05/02/2016 8-K Form 8-K - Current report
10/27/2015 8-K Quarterly results
Docs: "Pacira Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial Results -- Total Revenues of $62.2 Million in Third Quarter -- -- EXPAREL® Net Revenues of $59.7 Million in Third Quarter -- -- Conference Call Today at 9 a.m. ET --"
07/30/2015 8-K Quarterly results
Docs: "Pacira Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial Results"
04/30/2015 8-K Quarterly results
Docs: "Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenues of $56.0 Million and First Quarter 2015 Financial Results"
10/30/2014 8-K Quarterly results
Docs: "Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL Revenue of $50.2 Million and Third Quarter 2014 Results"
07/31/2014 8-K Quarterly results
Docs: "Pacira Pharmaceuticals, Inc. Reports Second Quarter 2014 Results: EXPAREL Revenue up 31% Over First Quarter"
05/01/2014 8-K Quarterly results
Docs: "Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenue of $34.4 Million and First Quarter 2014 Results"
08/06/2013 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy